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Introduction: Patients with early onset dementia (EOD), defined as dementia with
symptom onset at age<65, frequently present with atypical syndromes. However, the
epidemiologyof different EODpresentations, including variants ofAlzheimer’s disease
(AD) and frontotemporal dementia (FTD), has never been investigated all together in a
population-based study. Epidemiologic data of all-cause EOD are also scarce.
Methods:We investigated EOD epidemiology by identifying patients with EOD seen
in the extended network of dementia services of theModena province, Northern Italy
(≈700,000 inhabitants) from 2006 to 2019.
Results: In the population age 30 to 64, incidence was 13.2 per 100,000/year, based
on 160 new cases from January 2016 to June 2019, and prevalence 74.3 per 100,000
on June 30, 2019. Themost frequent phenotypeswere the amnestic variant of AD and
behavioral variant of FTD.
Discussion: EOD affects a significant number of people. Amnestic AD is the most fre-
quent clinical presentation in this understudied segment of the dementia population.
KEYWORDS
Alzheimer’s disease, clinical variants of dementia, early onset dementia, epidemiology, frontotem-
poral dementia, incidence, posterior cortical atrophy, prevalence, primary progressive aphasia
1 INTRODUCTION
The term “early onset dementia” (EOD) indicates dementia with
symptom onset before the age of 65, regardless of the underlying
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the original work is properly cited.
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dementia syndrome. EOD has a significant impact on patients and
families, which may include young children,1 as well as on employment
and income.2 General dementia care networks are frequently unable
to respond to the specific needs of patients with EOD, since they are
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tailored to older patientswith different social and family situations.3 In
addition, patients with EOD wait longer than patients with late-onset
dementia before receiving a correct diagnosis after symptom onset,
probably because they are not referred to dementia centers soon
enough and because reaching a correct diagnosis in these patients
is more challenging,4 since they frequently present with atypical
manifestations of dementia syndromes.5 As an example, in young
patients, Alzheimer’s disease frequently presents with a number of
non-amnestic variants, including posterior cortical atrophy (PCA)
and the logopenic variant of primary progressive aphasia (lvPPA),
compared to the more common amnestic presentation of dementia
due to Alzheimer’s disease (AD) in older patients.6
EOD prevalence has been variably reported ranging between 38
and 420 EOD cases per 100,000 in the age group 30 to 64,7 whereas
EOD incidence has been reported to vary between 2.4 and 22.6 new
cases per 100,000 per year.8,9 However, no previous population-based
studies on EOD have reported the epidemiology of different presenta-
tions or phenotypes of AD and frontotemporal dementia (FTD) spec-
trum.
Providing the epidemiology of all the different clinical presentations
of EOD would not only benefit medical professionals in their diagnos-
tic reasoningwhen facedwith youngpatientswith cognitive symptoms.
More importantly, it would also allow a better understanding of the
impact of different presentations on society and an improved planning
of dementia services and resource allocation.
We aimed to establish the prevalence and incidence of all-cause
EODaswell as of EODpresentations in aNorthern Italy community by
studying demographic and clinical features of patients with dementia
symptom onset before the age of 65.
2 METHODS
We conducted an epidemiological study in the province of Modena,
Northern Italy, which encompasses an area of about 2689 square kilo-
meters and includes 43municipalities. It covers a mountain area in the
Apennines andaplain area in the riverPovalley (PianuraPadana).Mod-
ena (≈186,000 inhabitants) is the larger city in the province, followed
byCarpi (≈72,000 inhabitants).OnJanuary1, 2019, theareahadapop-
ulation of 347,146 people30 to 64 years of age and 211,043 people 45
to64yearsof age, over a total populationof701,896 inhabitants. Three
years earlier, on January 1, 2016, there were 347,684 people 30 to 64
years of age and 200,402 people 45 to 64 years of age, over a total of
702,481 inhabitants.
We included in the study all the residents in the province ofModena
alive on census day (June 30, 2019), who had received a diagnosis
of dementia or major neurocognitive disorder with symptom onset
before age 65 from January 1, 2006 to June 30, 2019. Exclusion cri-
teria were co-existing diagnoses of developmental disorder (eg, Down
syndrome or cerebral palsy), longstanding history of major psychiatric
disorder (schizophrenia, bipolar disorder), cognitive impairment in the
context of another neurological disorder in which severe disability
was present due to non-cognitive symptoms (eg, multiple sclerosis,
RESEARCH INCONTEXT
∙ Systematic review: The authors reviewed the litera-
ture using traditional (eg, PubMed) sources and meet-
ing abstracts and presentations. There have been sev-
eral reports on the prevalence of all-cause early onset
dementia (EOD), fewer on its incidence. There are no
population-based studies on incidence and prevalence of
different presentations of EOD including clinical variants
of dementia due toAlzheimer’s disease (AD) or frontotem-
poral dementia. A large multisite longitudinal clinical and
biomarker study (not population-based) on a convenience
cohort of young adults with AD is currently ongoing (Lon-
gitudinal Early-Onset AD Study, LEADS).
∙ Interpretation: The present population-based study
established the incidence and prevalence of all the
presentations of EOD, including different variants of AD.
∙ Future directions: Up-to-date knowledge of the epidemi-
ology of EOD is the first step to understand its impact
on patients, families, and society. This study complements
current ongoing biomarker and clinical studies in filling the
gap in theknowledgeonanunderstudied faceof dementia.
cerebrovascular disease with severe motor disability), age younger
than 30, and residence outside the province ofModena on census day.
Patient recruitment involved the extended network of demen-
tia services existing in the province of Modena, which includes
two hospital-based outpatient cognitive neurology clinics in the two
neurology services (Ospedale Civile di Baggiovara in Modena and
Ospedale Ramazzini in Carpi, respectively) and eight outpatient geri-
atric memory clinics (all named “Centro per i Disturbi Cognitivi e
le Demenze” [CDCD]). CDCDs reach patients living at home and in
nursing homes, and coordinate the care of patients in daytime ser-
vices and one special care unit for behavioral disturbances. Patients
are followed periodically in their CDCD at least every 6 months
(this is also related to the Italian regulation regarding prescription
of cholinesterase inhibitor and neuroleptic medications that requires
periodic medical checks). Because it is not infrequent that young
patients with cognitive disorders and other neurological accompa-
nying symptoms may be first referred to movement disorders or
motor neuron disease clinics, all these clinics from the two neurol-
ogy services of the province were also involved in the recruitment.
All these services extensively cover the entire province and are part
of the Italian National Health System (Sistema Sanitario Nazionale).
Patients with cognitive symptoms who are younger than 65 years
are usually referred to neurologic CDCDs, whereas older patients
are referred to geriatric CDCDs. Referrals to CDCDs can be made
by either general practitioners or specialists such as Psychiatrists (as
frequently is the case for patients presenting with behavioral symp-
toms). The dementia care network is organized so that patients 65
and older can also be referred to neurologic CDCD (either by general
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practitioners or geriatric CDCD) in case of diagnostic uncertainty,
whereas EOD patients with severe functional impairment or living in
nursing homes are referred to geriatric CDCD.
We identified retrospectively all EODpatients fromJanuary1, 2006
to December 31, 2016, and prospectively all new EOD patients from
January 1, 2017 to June 30, 2019. We adopted a mixed recruitment
strategy because we were interested not only in EOD epidemiology,
but also wanted to estimate the needs of all the living patients and
their families with the ultimate aim of optimizing resource allocation.
Therefore, after having received ethical approval for the current study,
we commenced prospective recruitment of all new EOD cases but also
searched retrospectively for all the living cases diagnosed in the previ-
ous 10 years. The definition of EOD cases and inclusion and exclusion
criteriawere consistent for the retrospective and theprospective parts
of the study.
In the retrospective part of the study we identified all patients with
a diagnosis of dementia occurring in the 2006 to 2016 period with an
onset of cognitive or behavioral symptoms before age 65 seen in the
neurologic CDCDs, geriatric CDCDs, movement disorders clinics, and
motor neuron disease clinics, by review of their medical records and,
whenever possible, by direct assessment of the patients. This allowed
us to confirm a diagnosis of dementia or major neurocognitive disor-
der as defined by the Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition (DSM-5),10 as well as to ascertain the specific
clinical diagnosis and the date of onset of symptoms. The review of
the clinical records and/or assessment of patients was performed by
three neurologists (AC, GV, and MT) with clinical expertise in cogni-
tive disorders. Each case was collegially discussed to reach consen-
sus on the diagnosis. In the prospective part of the study we recruited
all patients with onset of cognitive or behavioral symptoms before
age 65 referred to the aforementioned facilities between January 1,
2017 and June 30, 2019. All these patients were assessed by a neu-
rologist with clinical expertise in cognitive disorders of the two neu-
rologic CDCDs (AC, GV, MT, GZ, MC). The diagnostic workup included
neurological examination, extended neuropsychological assessment,
and structural brain imaging with magnetic resonance imaging (MRI)
for all patients (computerized tomography [CT] scan was performed
only if MRI was contraindicated). In addition, when clinically indicated,
patients also underwent lumbar puncture for measurement of cere-
brospinal fluid (CSF) total tau, phosphorylated tau, and 1-42 amyloid
beta ([Aβ], routinely performed at the two hospital-based cognitive
neurology clinics inModena Province since 2007), fluorodeoxyglucose
(FDG) positron emission tomography (PET) imaging or amyloid PET
imaging (performed since 2006 and 2013, respectively), and genetic
analysis (performed since 2006).
For each EOD case, diagnosis of the specific type of demen-
tia was established through the use of most recent clinical
criteria for each dementia syndrome, including AD,11 vascu-
lar dementia (VaD),12,13 behavioral variant of frontotemporal
dementia (bvFTD),14 primary progressive aphasia (PPA) and its
variants,15 posterior cortical atrophy (PCA),16 Lewy body dementia
(LBD),17 Parkinson disease dementia,18 dementia in Huntington
disease (HD),19 progressive supranuclear palsy (PSP),20 corti-
cobasal syndrome (CBS),20 dementia in Creutzfeldt-Jakob Disease
(JCD),21 leukoencephalopathy,22 and cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL).23 The diagnosis of AD was supported by at least one
biomarker suggestive of amyloid deposition (either CSF or amyloid-
PET) in the largemajority of cases. Themacro-classificationof different
syndromes was based on Elahi and Miller.24 Because clinical criteria
may have evolved over time, for the retrospective part of the study the
diagnoses were systematically assessed and harmonized according
to the most recent criteria, upon consensus between the neurologists
reviewing the cases. As anexample, living casesof the logopenic variant
ofPPA (or lvPPA),whichwouldhavebeen included in theFTDspectrum
prior to 2011, upon review were reclassified as a variant of dementia
due to AD. Dementia cases that did notmeet criteria for a specific type
of dementia were classified as “not otherwise specified” (or NOS).
We collected demographic and clinical characteristics for each EOD
case. Education was defined as the number of years of education.
Age at symptom onset was defined as the referred age (by patient or
caregiver) when the first cognitive or behavioral symptom had been
observed by the patient themselves or by the caregiver. Age at diagno-
siswas defined as the agewhen the patientwas diagnosedwith demen-
tia for the first time, irrespective of the specific type of dementia syn-
drome. For patients with a clinical diagnosis of mild cognitive impair-
ment (MCI) or mild neurocognitive disorder (ie, presence of measur-
able deficit on at least one cognitive domain that does not affect every-
day functioning) the age at diagnosis was the age when they converted
to dementia, regardless of the fact that biomarkers suggestive of a
specific underlying neurodegenerative pathophysiology may have also
been available in the MCI phase (eg, MCI with evidence of underlying
AD pathophysiology).25
We computed both crude and age- and sex-adjusted incidence rates
with reference to the entire period January 1, 2016 through June 30,
2019, and to each of these years. For both calculations, we used the
Modena province resident population on January 1 of each year from
2016 to 2019,26 after exclusion of previously diagnosed EOD cases
from the denominators. The rate was then directly standardized to the
2013European standardpopulation,27 taking into account age and sex.
We focused on the most recent years to avoid biases due to possible
changes in diagnostic sensitivity over time.
We computed the crude and age- and sex-adjusted prevalence rate
at census date (June 30, 2019), using as denominator the residing pop-
ulation on January 1, 2019, which was themost recent available.
To allow comparison with previous studies, we computed incidence
and prevalence rates for the age groups 30 to 44 and 45 to 64 years,
and for the entire population at risk, 30 to 64 years.
When reporting incidence and prevalence rates on 100,000 inhab-
itants, we considered as denominator the entire population of Modena
province from age 0, whereas when reporting incidence and preva-
lence rates on 100,000 persons at risk, we used as denominators the
resident population in the corresponding age subgroups (30 to 44,
45 to 64, and 30 to 64 years). Subjects who did not meet inclusion
criteria because the predominant etiology of their disability was a
developmental disorder, or a longstanding history of major psychiatric
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TABLE 1 Prevalence of all-cause EOD at census date by range of age at onset and sex
Prevalent cases at June 30, 2019
Age and sex specific prevalence at June 30, 2019
(per 100.000 inhabitants)
Age range (year) Total M F Total M F
30-34 0 0 0 0 0 0
35-39 1 0 1 2.3 0 4.6
40-44 4 1 3 7.4 3.7 11.1
45-49 10 7 3 16.9 23.5 10.2
50-54 29 11 18 50.8 38.4 63.2
55-59 84 44 40 164.5 177.1 152.5
60-64 130 60 70 296.4 285.3 306.7
disorder, or another neurological disorder such as multiple sclerosis
or cerebrovascular accident, were not removed from the population
on which prevalence and incidence were calculated. The study was
conducted in accordance with local clinical research regulations, and
conformed to the Declaration of Helsinki (Study Number 186/2016
approved by the local ethical committee).
3 RESULTS
3.1 EOD incidence
From January 1, 2016 to June 30, 2019, we identified 160 incident
cases of EOD, with a median age of onset of 60 years (interquartile
range [IQR] 58 to 63). All-cause EOD annual crude incidence rate
was 6.48 cases/100,000 inhabitants and annual age- and sex-adjusted
incidence was 6.49 (95% confidence interval [CI] 6.46, 6.52) during
the 2016 to 2019 period, corresponding to 46 new cases per year in
the overall Modena province population. Considering each year sepa-
rately, age- and sex-adjusted incidence was 5.98 cases/100,000 inhab-
itants (95% CI 5.93, 6.04) in 2016, 5.80 (95% CI 5.75, 5.86) in 2017,
7.52 (95% CI 7.46, 7.58) in 2018, and 6.81 (95% CI 6.72, 6.89) in 2019.
When the analyses for age groupwere stratified, annual age- and sex-
adjusted incidence rate was 2.94/100,000 (95% CI 2.81, 3.07) in the
30 to 44 age group, 22.06 (95% CI 21.96, 22.15) in the 45 to 64 age
group, and13.19 (95%CI13.13, 13.25) in thewhole30 to64age group.
Notably, the rate increasedwith age from1.0 in the 40 to 44 age group,
to 6.7 in the 50 to 54 group, to 59.8 in the 60 to 64 group.
3.2 EOD prevalence
We identified 258 patients with a clinical diagnosis of EOD
(male/female: 123/135) in Modena province at June 30, 2019.
Thirty-one patients did not meet inclusion criteria because the pre-
dominant etiology of their disability was a developmental disorder
(n = 3), a longstanding history of major psychiatric disorder (n = 11),
or another neurological disorder such as multiple sclerosis (n = 4) or
cerebrovascular accident (n= 13).
The resulting EOD crude prevalence was 36.43/100,000 inhabi-
tants and the age- and sex-adjusted prevalence was 36.41/100,000
inhabitants (95% CI 35.01, 37.81). Stratifying the analyses for
age group, EOD age- and sex-adjusted incidence prevalence was
3.69/100,000 (95% CI 2.67, 4.71) in the 30 to 44 age group, 119.85
(95% CI 115.20, 124.49) in the 45 to 64 age group, and 74.30 (95% CI
71.45, 77.16) in the whole 30 to 64 age group. Table 1 reports preva-
lence of all-cause EOD by age and sex.
Among the 258 prevalent cases, median age at onset of the first
cognitive or behavioral symptom was 60 years (IQR 56 to 63). Median
age at dementia diagnosis was 63 years (IQR 59 to 66). Table 2
reports demographic characteristics of the prevalent cases. Ninety-
nine patients (38.4%) were first cognitively assessed when they were
still in theMCI stage. The remaining 159 patients were assessed when
a dementia syndrome could already be diagnosed. Of all cases, 157
had been retrospectively identified. Of these, 89 were referred to one
of the two recruiting neurologic CDCDs and examined by one of the
study neurologists, whereas 68 were first seen in geriatric CDCDs
and then referred to the neurology clinics, where they were directly
examined by one of the study neurologists (n = 10) or received care-
ful reviewofmedical records (n=58). The remaining101patientswere
prospectively identified andexaminedbyoneof the studyneurologists.
Among all cases, 47 had been seen previously in a psychiatric clinic and
then referred to one of the CDCDs. Of these, 10 eventually received
a diagnosis of AD dementia, 31 of a disease of the FTD spectrum, and
7received other dementia diagnoses.
All identified patients underwent brain imaging either with struc-
tural MRI (n = 206) or CT scan (n = 52). Among all cases, 131 also
had lumbar puncture for measurement of CSF biomarkers, 51 had
PET imaging (48 FDG, 3 amyloid), and 41 genetic analysis leading
to the identification of a genetic cause in 14 cases (4 AD, 4 FTD
spectrum, one hereditary diffuse leukoencephalopathy with spheroids
[HDLS], 2 CADASIL, and 3HD). At the last visit performed within 6
months before census date, 88 patients (34.1%) had had a demen-
tia of mild severity (defined as having Mini-Mental State Exami-
nation score[MMSE] >21), 83 (32.1%) had dementia of moderate
severity (MMSE 10 to 20), 50 (19.3%) had dementia of advanced
severity (MMSE <10), and for 37 patients (14.3%) MMSE was not
available.
CHIARI ET AL. 5
TABLE 2 Demographic and clinical characteristics of the 258 prevalent cases at census date
Total (n= 258) Male (n= 123) Female (n= 135)
Characteristics of study
subjects Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Age at onset, years 58.8 (5.0) 60 (56–63) 58.8 (4.9) 59 (57–63) 58.8 (5.2) 60 (56–63)
Age at diagnosis, years 62.0 (5.5) 63 (59–66) 62 (5.5) 63 (59–66) 62.1 (5.6) 63 (59–66)
Months between onset
and diagnosis
38.7 (29.2) 31 (18–51) 37.9 (30.0) 29 (17–50) 39.5 (25.5) 33 (18–52)
Years of educationa 9.0 (3.8) 8 (5–13) 9.3 (3.6) 8 (7–13) 8.8 (4.0) 8 (5–13)
MMSE score at
diagnosisa
22.0 (5.2) 23 (19–26) 22.7 (5.5) 24 (20–26) 21.5 (4.8) 22 (19–26)
IQR, interquartile range;MMSE,Mini-Mental State Examination; SD, standard deviation.
aYears of education andMMSE score available in 224 (male/female: 110/114) and 189 (male/female: 88/101) patients, respectively.
TABLE 3 Clinical diagnoses of prevalent cases
Clinical diagnosis N % M/F
Total 258 100 123/135
AD 113 43.8 36/77
FTD spectrum 78 30.2 44/34
Vascular dementia 24 9.3 16/8
Lewy body dementia 9 3.5 5/4
Leukoencephalopathy 7 2.7 5/2
Parkinson disease dementia 7 2.7 6/1
Alcoholic dementia 4 1.5 3/1
Cerebral amyloid angiopathy 3 1.2 2/1
Dementia in Huntington disease 3 1.2 2/1
NOS 10 3.9 4/6
AD, Alzheimer’s dementia; FTD, frontotemporal dementia; NOS, dementia
not otherwise specified.
3.3 Clinical variants
AD was the most frequent clinical diagnosis, followed by clinical syn-
dromes of the FTD spectrum, VaD, and LBD (Table 3). Other patholo-
gies such as leukoencephalopathies including one case of HDLS and
two cases of CADASIL, three cases of HD, and one case of JCD were
also found.
Among all AD dementia patients, 69.9% had amnestic onset, 17.7%
had lvPPA, 7.9% had PPA, and 4.4% had behavioral/dysexecutive vari-
antAD.Among all FTDspectrumpatients, 62.8%had thebvFTD, 15.3%
semantic variant of primary progressive aphasia (svPPA), 2.5% had
agrammatic/non-fluent primary progressive aphasia (nfvPPA), 7.6%
had FTD with amyotrophic lateral sclerosis (FTD-ALS) either with
behavioral or non-fluent onset, 6.4%hadCBS, and 5.3%hadPSP.When
looking at all the clinical variants together, the most frequent clini-
cal presentation of EOD was the amnestic variant of AD, followed by
bvFTD, lvPPA, svPPA, and PCA. There were no significant differences
in diagnostic delay between the different clinical syndromes (P= .252).
As expected, CSF Aβ 1-42 median value was 445 pg/mL in AD demen-
tia patients (IQR 154), whereas it was 865 pg/mL in non-AD dementia
patients (IQR 452). CSF total-tau median value was 567 pg/mL in AD
(IQR 426) and 265 pg/mL in non-AD (IQR 257). Phospho-tau median
value was 79 pg/mL in AD (IQR 44) and 44 pg/mL in non-AD (IQR 32).
Prevalence of AD dementia only was 32.55/100,000 in the whole
30 to 64 age group and 53.07 in the 45 to 64 age group. Prevalence
of syndromes of the FTD spectrumwas 22.47/100,000 in thewhole 30
to 64 age group and 36.49 in the 45 to 64 age group. Prevalence cal-
culated considering these two common neurodegenerative dementia
syndromes (ADdementia and FTD) togetherwas 55.02/100,000 in the
whole 30 to 64 age group and89.56/100,000 in the 45 to 64 age group.
Table 4 reports the case number, prevalence, and incidence of the dif-
ferent clinical variants of AD and FTD spectrum.
4 DISCUSSION
We report the incidence and prevalence of all the phenotypes of EOD
including different variants of ADand FTDby conducting a population-
based study of all the cases of dementia with onset before age 65 in
the province ofModena, Northern Italy.We specifically aimed to inves-
tigate the epidemiology of all the different clinical presentations of
dementia in young patients, including clinical variants of both AD and
FTD, which—to the best of our knowledge—have never been inves-
tigated all together. We found that, among all the presentations, the
most frequent is the amnestic variant of AD, followed by the behav-
ioral variant of FTD, and by the logopenic variant of AD. This observa-
tion may have important clinical implications, since knowing the rela-
tive frequency of presentations will directly benefit the reasoning of
clinicians facedwith young patients with cognitive symptoms.
We found an overall EOD incidence of 6.5/100,000 inhabitants per
year by adjusting for the demographical features (sex and age) of the
European standard population. To our knowledge, no previous studies
have corrected incidence for the demographic features of the specific
populations in which they were carried out, limiting the possibility to
truly compare results among different studies. We found a crude inci-
dence of EOD of 13.2/100,000 persons at risk in the age range 30 to
64, and 22.1/100,000 persons at risk in the age range 45 to 64. These
data are consistent with those reported by the most recent incidence
studyonEODconducted in theGirona regionof Spain using adementia
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TABLE 4 AD and FTD presentations: crude incidence (period January 1, 2016 to June 30, 2019) and crude prevalence on census day (June 30,












AD 113 (100) 32.6 61 (100) 5.0
Amnestic 77 (68.1) 22.2 45 (73.8) 3.7
Posterior cortical atrophy (PCA) 8 (7.1) 2.3 2 (3.3) 0.16
Logopenic variant (lvPPA) 20 (17.8) 5.8 10 (16.4) 0.8
Behavioral/dysexecutive 4 (3.5) 1.2 / /
NOS 4 (3.5) 1.2 4 (6.5) 0.3
FTD SPECTRUM 78 (100) 22.5 52 (100) 4.3
Behavioral variant (bvFTD) 49 (62.8) 14.1 32 (61.5) 2.6
Semantic variant (svPPA) 11 (14.1) 3.2 9 (17.3) 0.74
Non-fluent primary progressive aphasia
(nfvPPA)
2 (2.6) 0.6 2 (3.8) 0.16
FTD-ALS 6a (7.7) 1.7 4b (7.7) 0.32
Corticobasal syndrome (CBS) 5 (6.4) 1.4 2 (3.8) 0.16
Progressive supranuclear palsy (PSP) 4 (5.1) 1.2 3 (5.9) 0.25
NOS 1 (1.3) 0.3 / /
N, number of subjects.
NOS, not otherwise specified.
a
N= 4 bvFTD andN= 2 nfvPPA variants.
b
N= 3 bvFTD andN= 1 nfvPPA variants.
registry, which found incidences of 13.4/100,000 person-years in the
age group 30 to 64 and 22.8/100,000 person-years in the age group 45
to 64.8 They are also comparable but slightly smaller to those obtained
from the Rochester Epidemiology Project,28 which also included cases
with cognitive impairment secondary to brain tumors or chronic men-
tal illness that, instead, we purposefully excluded from our study. Our
crude incidence for the 45 to 64 age group (22.1/100,000) is almost
twofold higher than the incidence of 11.5/100,000 reported by a study
of all cases seen in anhospital-based study in theUK,29 possibly reflect-
ing a higher rate of physician consultation and specialist referral in Italy
compared to other European countries.29
We found a prevalence of all-cause EOD of 74.3/100,000 persons
at risk in the age range 30 to 64 and 119.9/100,000 persons at risk in
the age range 45 to 64. This prevalence overlaps with those obtained
in two recent studies conducted in Norway7 and Australia30 but is
greater than those reported in older studies conducted in theUK31 and
Japan.32 Of interest, even when considering the diagnoses of AD and
FTD dementia only, we found a greater prevalence compared to that
reported by the only prevalence study on EOD conducted in Italy, in
the Brescia province.33 That we found greater prevalence relative to
older studies may reflect the general improvement in dementia identi-
fication and diagnosis seen over the past decade worldwide, which is a
consequence not only of educational interventions to improve primary
care practice,34 but also of the general improvement in the diagnostic
ability through theuseof biomarkers,whichwerenot easily available in
clinical practices a decade ago. In addition, the high prevalence
reported in the present study may be related to the high level of diag-
nostic accuracy and to the widespread recruitment based on an inclu-
sive and easily accessible dementia care network. Alternatively, the
greater prevalencemay reflect a really larger incidence and/or survival
in our population.
We found that the most frequent cause of EOD is AD demen-
tia. This is consistent with previous epidemiological studies on EOD
incidence8,35 and with most studies on EOD prevalence.7,36 The few
prevalence studies that found that ADdementiawas the second preva-
lent cause of EOD after VaD were either not population-based but
conducted on hospital-based cohorts,37,38 or carried out in countries
such as Japan,32 with a known greater incidence of stroke relative to
the Caucasian population in presenile ages.39 A recent EOD preva-
lence study, which found AD second to alcohol-related dementia, may
have been biased by over-diagnosis of the latter by clinicianswhowere
not dementia specialists, as stated by the authors.30 Of interest, in
our series, there were no differences in diagnostic delay between the
different clinical syndromes, suggesting that even challenging cases
such as those presenting with behavioral symptoms were identified
promptly by the study network.
With regard to the clinical variants of AD dementia, their inci-
dence or prevalence has not been investigated in population-based
studies yet, possibly because their characterization is relatively recent
and only subsequent to the advent of AD biomarkers.15,16 In our
population-based study the non-amnestic variants represented 34%
of all AD dementia cases, with lvPPA being the most frequent. This is
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comparable to one of the two previous hospital-based studies con-
ducted on cohorts of patients referred to dementia clinics, which
reported a relative proportion of non-amnestic presentations of
32%,40 but is lower than the one conducted on consecutive cases seen
at a specialist dementia center, which reported a proportion of non-
amnestic presentations of 64%6 andmight have been biased by a focus
on atypical presentations. As for the FTD spectrum, one previous study
conducted in2007-2009 reported the incidenceof bvFTD, svPPA,CBS,
and PSP, but not of nfvPPA and ALS-FTD.8 Our incidence values are
consistent for CBS and PSP, but higher for bvFTD and svPPA, possibly
reflecting the fact that the refinement of diagnostic criteria for the lat-
ter variants was subsequent to that study and that our diagnosis was
based on an in-depth clinical assessment and supported by the use of
biomarkers. There are no comprehensive studies on prevalence of the
clinical presentations of the FTD spectrum.
A major strength of our study was the ability to merge several
sources of health data from a capillary network of centers for the diag-
nosis and care of dementia, movement disorders and motor neuron
disease, and residential care facilities, which allowed the identification
of all EOD cases in a defined population. Another strength is that all
cases underwent in-depth clinical assessment in which the diagnosis
was often supported by the use of biomarkers thus improving diagnos-
tic accuracy. Finally, all caseswereeither examineddirectly or reviewed
by a team of neurologists of a third-level dementia center, to ensure
consistency in the diagnosis.
The present study also has limitations. First, we used a mixed
retrospective-prospective design for case inclusion, possibly leading
to lower sensitivity in the earlier years of the study. For this reason,
we purposefully decided to calculate incidence over the last 3.5 years
of the study period, during which we detected stable incidence rates
over time. Second, we acknowledge that we might have underesti-
mated cases of alcoholic dementia because in the Modena province
patients with suspected alcohol abuse are usually referred to specific
psychiatric services and not to the dementia network. However, we
did include those patients with alcoholic dementia in whom demen-
tia was the principal consequence of alcohol abuse, that is, they had
pure alcoholic dementia, not confounded by other comorbidities. Third,
we purposefully excluded patients with cognitive impairment and a
long history of psychiatric disorders; this might have led us to under-
estimate cases of neurodegenerative dementia syndromes possibly co-
occurring in those patients. However, these patients were not included
in previous studies.8,30,33 In addition, psychiatric services generally
refer to our dementia network patients with suspected neurocogni-
tive disorders (for the present study 47 EOD were included from that
source); therefore we do not expect to have substantially missed cases
for this reason. Finally, we did not use cross-matching with data from
other provinces of the Emilia Romagna region and may have missed
patients referred to dementia centers outside of theModena province.
However, this is very unlikely, because dementia drug distribution and
social care facilities in Italy are strictly linked to the place of residence.
The result of this population studymay contribute to a better under-
standing of epidemiology and clinical management of EOD, and its dif-
ferent clinical presentations, thus helping to optimize cost-effective
dementia care organization, andultimately to improvequality of life for
patients and caregivers.
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